

ACTA MEDICINAE 5/2013 REVMATOLOGIE

Kompletní literatura

- 2 **Očkování pacientů s revmatickými onemocněními v České republice**
prof. MUDr. Karel Pavelka, DrSc. | MUDr. Erik Moster | MUDr. Helena Ptáčková Revmatologický ústav, Praha
- 2 **Piascledine 300**
MUDr. Marta Olejárová Revmatologický ústav, Praha
- 2 **Vliv biologické léčby na zlepšení kvality života nemocných s revmatoidní artritidou**
MUDr. Jakub Závada, Ph.D. Revmatologický ústav, Praha
- 3 **Tocilizumab oproti adalimumabu v monoterapii u revmatoidní artritidy**
prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha
- 3 **Subkutánní forma abataceptu**
MUDr. Zdeněk Fojtík, Ph.D. Revmatologická ambulance, Interní hematologická a onkologická klinika a LF MU Brno
- 4 **Farmakologická léčba osteoporózy**
MUDr. Petr Hrdý | MUDr. Pavel Novosad MEDIEKOS Labor, s. r. o., Osteocentrum, Zlín
- 5 **Denosumab v klinické praxi**
MUDr. Olga Růžičková Revmatologický ústav, Praha
- 7 **Stručný přehled terapie bolesti u revmatických chorob**
MUDr. Hana Ciferská, Ph.D. | MUDr. Olga Šléglová Revmatologický ústav, Praha
- 8 **Imunogenicitá inhibitorů TNF α v léčbě revmatoidní artritidy**
MUDr. Rudolf Horváth, Ph.D. Ústav imunologie 2. LF UK a FN Motol, Praha, Revmatologický ústav, Praha
- 10 **Kalcium a vitamin D v prevenci a léčbě glukokortikoidy indukované osteoporózy**
MUDr. Olga Růžičková Revmatologický ústav, Praha
- 11 **Ledvinné manifestace u revmatických chorob**
MUDr. Hana Ciferská Revmatologický ústav, Praha
MUDr. Jan Vachek Klinika nefrologie VFN, Praha
- 12 **Monitorace aktivity revmatoidní artritidy pomocí muskuloskeletálního ultrazvuku**
MUDr. Jana Hurňáková Revmatologický ústav Praha
- 13 **Statiny a imunitně zprostředkované myopatie**
MUDr. Heřman Mann Revmatologický ústav, Praha
- 14 **Moderní terapie ANCA-pozitivních vaskulitid**
doc. MUDr. Radim Bečvář, CSc. Revmatologický ústav, Revmatologická klinika 1. LF UK, Praha

Očkování pacientů s revmatickými onemocněními v České republice

prof. MUDr. Karel Pavelka, DrSc. | MUDr. Erik Moster | MUDr. Helena Ptáčková

Revmatologický ústav, Praha

- 1 Dixon, W. G. – Watson, K. – Lunt, M., et al.: Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics register. *Arthritis Rheum*, 2006, 4, s. 2368–2376.
- 2 Bongartz, T. – Sutton, A. J. – Sweeting, M. J., et al.: Anti TNF therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and metaanalysis of rare harmful effects in randomized controlled trials. *JAMA*, 2006, 295, s. 2275–2285.
- 3 Listing, J. – Strangfeld, A. – Kary, S., et al.: Infections in patients with rheumatoid arthritis treated with biologic agents. *Arthritis Rheum*, 2005, 52, s. 3403–3412.
- 4 Askling, J. – Fored, C. M. – Brandt, L., et al.: Time-dependent increase in risk of hospitalization with infection among Swedish RA patients treated with TNF antagonists. *Ann Rheum Dis*, 2007, 66, s. 1339–1344.
- 5 van Assen, S. – Agmon-Levin, N. – Elkayam, O., et al.: EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. *Ann Rheum Dis*, 2011, 70, s. 414–422.
- 6 Gardam, M. A. – Keystone, E. C. – Menzies, R., et al.: Anti-tumor necrosis factor agents and tuberculosis: mechanism of action and clinical management. *Lancet Infect Dis*, 2003, 3, s. 148–156.
- 7 Carmona, L. – Gomez-Reino, J. J. – Rodriguez-Valverde, V., et al.: Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. *Arthritis Rheum*, 2005, 52, s. 1766–1772.
- 8 Saag, K. G. – Teng, G. G. – Patkar, N. M., et al.: American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. *Arthritis Rheum*, 2008, 59, s. 762–784.
- 9 Holvast, A. – Huckriede, A. – Wilschut, J., et al.: Safety and efficacy of influenza vaccination in SLE patients with quiescent disease. *Ann Rheum Dis*, 2006, 65, s. 913–918.
- 10 Bingham, C. O. – Looney, R. J. – Deodhar, A., et al.: Immunization responses in RA patients treated with rituximab: results from a controlled clinical trial. *Arthritis Rheum*, 2010, 62, s. 64–74.
- 11 Kapetanovic, M. C. – Saxne, T. – Sjöholm, A.: Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. *Rheumatology (Oxford)*, 2006, 45, s. 106–111.
- 12 Chlíbek, R.: Očkování rizikových skupin pacientů proti pneumokokovým infekcím. *Medicína pro promoci*, 2013, 14, s. 44–48.
- 13 Duchet-Niedzolja, P. – Launay, O., et al.: Vaccination in adults with autoimmune disease and/or drug related immune deficiency results of the GEVACCIM Delphi survey. *Vaccine*, 2009, 27, s. 1523–1529.
- 14 Vencovský, J.: Bezpečnost biologické léčby. Doporučení České revmatologické společnosti. *Čes Revmatol*, 2009, 17, s. 146–160.
- 15 Fleischmann, R. M.: Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab. *Semin Arthritis Rheum*, 2009, 38, s. 265–280.
- 16 Kuruma, K. A. – BoirBa, E. F. – Lopes, H. M., et al.: Safety and efficacy of hepatitis B vaccine in SLE patients. *Lupus*, 2007, 16, s. 350–354.
- 17 Tam, L. – Chan, P. S. – Ho, S.: Natural history of cervical human papillomavirus infection among women with systemic lupus erythematoses. *Ann Rheum Dis*, 2009, 68, s. 128.
- 18 Karpelovsky, J. S. – Alexander, A. G. – Peek, S. D., et al.: Surgical complications of bacille Calmette: guerin infection in HIV-infected children: time for a change in policy. *A Afr Med J*, 2008, 98, s. 801–804.

Piasclidine 300

MUDr. Marta Olejárová Revmatologický ústav, Praha

- 1 Maheu, E. – Cadet, C. – Marty, M., et al.: Randomised, controlled trial of avocado-soybean unsaponifiables (Piasclidine) effect on structure modification in hip osteoarthritis: the ERADIAS study. *Ann Rheum Dis*, 2013, 0, 1–9, doi:10.1136/annrheumdis-2012-202485.

Vliv biologické léčby na zlepšení kvality života nemocných s revmatoidní artritidou

MUDr. Jakub Závada, Ph.D. Revmatologický ústav, Praha

- 1 Drossaers-Bakker, K. W. – de Buck, M. – van Zeven, D. – Zwiderman, A. H. – Breedveld, F. C. – Gates, J. M.: Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. *Arthritis Rheum*, 1999, 42, s. 1854–1860.
- 2 Sokka, T. – Kautiainen, H. – Hannonen, P. – Pincus, T.: Changes in Health Assessment Questionnaire disability scores over five years in patients with rheumatoid arthritis compared with the general population. *Arthritis Rheum*, 2006, 54, s. 3113–3118.
- 3 Bellamy, N. – Boers, M. – Nelson, D. – Fries, J. F. – Furst, D. – Henry, D. – Liang, M. – Lovell, D. – March, L. – Strand, V., et al.: Health status instruments/utilities. *J Rheumatol*, 1995, 22, s. 1203–1207.
- 4 Bruce, B. – Fries, J. F.: The Stanford Health Assessment Questionnaire: Dimensions and Practical Applications. *Health and Quality of Life Outcomes*, 2003, 1, s. 20.
- 5 Bruce, B. – Fries, J. F.: The Health Assessment Questionnaire (HAQ).

- Clinical and Experimental Rheumatology*, 2005, 23, s. S14–S18.
- 6 **Ware, J. E. jr. – Sherbourne, C. D.:** The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care*, 1992, 30, s. 473–483.
 - 7 **McHorney, C. A. – Ware, J. E. jr. – Raczek, A. E.:** The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. *Med Care*, 1993, 31, s. 247–263.
 - 8 **The EuroQol Group:** EuroQol—a new facility for the measurement of health-related quality of life. *Health Policy*, 1990, 16, s. 199–208.
 - 9 **Dolan, P. – Hudec, C. – Kind, P., et al.:** The time trade-off method: results from a general population study. *Health Econ*, 1996, 5, s. 141–154.
 - 10 **Strand, V. – Singh, J. A.:** Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. *Drugs*, 2010, 70, s. 121–145.
 - 11 **Maini, R. N. – Breedveld, F. C. – Kalden, J. R., et al.:** Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. *Arthritis Rheum*, 2004, 50, s. 1051–1065.
 - 12 **Kekow, J. – Moots, R. J. – Emery, P., et al.:** Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: The COMET trial. *Ann Rheum Dis*, 2010, 69, s. 222–225.
 - 13 **Keystone, E. C. – Kavanaugh, A. F. – Sharp, J. T., et al.:** Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. *Arthritis Rheum*, 2004, 50, s. 1400–1411.
 - 14 **Fleischmann, R. – Vencovsky, J. – van Vollenhoven, R., et al.:** Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. *Ann Rheum Dis*, 2009, 68, s. 805–811.
 - 15 **Genovese, M. C. – Han, C. – Keystone, E. C. – Hsia, E. C. – Buchanan, J. – Gathany, T. – Murphy, F. T. – Wu, Z. – Parasuraman, S. – Rahman, M. U.:** Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study. *J Rheumatol*, 2012, 39, s. 1185–1191.
 - 16 **Závada, J. – Uher, M. – Hejduk, K. – Vencovský, J. – Pavelka, K. – kolektiv lékařů biologických center:** Zdravím podmíněná kvalita života u pacientů s revmatoidní artritidou v průběhu prvního roku anti-TNF léčby – výsledky z registru biologické léčby ATTRA. *Česká revmatologie*, 2013 (přijato k publikaci).
 - 17 **Westhovens, R. – Cole, J. C. – Li, T., et al.:** Improved health related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial. *Rheumatology (Oxf)*, 2006, 45, s. 1238–1246.
 - 18 **Keystone, E. – Burmester, G. R. – Furie, R., et al.:** Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. *Arthritis Rheum*, 2008, 59, s. 785–793.
 - 19 **Kremer, J. – Pope, J. – Tony, H.-P., et al.:** Tocilizumab (TCZ) improves quality of life (QOL) in patients with rheumatoid arthritis (RA) who had inadequate response (IR) to TNF antagonists. *Arthritis Rheum*, 2008, 5, dopl. 991.

Tocilizumab oproti adalimumabu v monoterapii u revmatoidní artritidy

prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha

- 1 **Gabay, C. – Emery, P. – Vollenhoven R., et al.:** Tocilizumab Monotherapy vs. Adalimumab Monotherapy for the Treatment of Rheumatoid Arthritis (ADACTA): A randomised, double-blind, controlled phase 4 trial. [dx.doi.org/10.1016/S0140-6736\(13\)60250-0](https://doi.org/10.1016/S0140-6736(13)60250-0).
- 2 **Klareskog, L. – van der Heijde, D. – de Jager, J. P., et al. (8. Pavelka, K.):** Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. *The Lancet* 2004, 363, s. 675–681.
- 3 **Breedveld, F. C. – Weisman, M. H. – Kavanaugh, A. F. – Cohen, S. B. – Pavelka, K. – van Vollenhoven, R. – Sharp, J. – Perez and Spencer-Green, G. T.:** The PREMIER Study. A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. *Arthritis Rheumatism*, 2006, 54, 1, s. 26–37.
- 4 **Jones, G. – Sebba, A. – Gu, J., et al.:** Comparison of tocilizumab monotherapy vs. methotrexate monotherapy in patients with moderate to severe RA. The Ambition study. *Ann Rheum Dis*, 2010, 69, s. 88–96.
- 5 **Yazici, Y. – Shi, N. – John, A.:** Utilization of biologic agents in rheumatoid arthritis in the US: analysis of prescribing patterns in 16752 newly diagnosed patients and patients new to biologic therapy. *Bulletin of the NYU Hospital for Joint Diseases*, 2008, 66, 2, s. 77–85.
- 6 **Smolen, J., et al.:** Eular recommendations for the treatment of RA. *EULAR*, Madrid, 2013.

Subkutánní forma abataceptu

MUDr. Zdeněk Fojtík, Ph.D.

Rheumatologická ambulance, Interní hematologická a onkologická klinika a LF MU Brno

- 1 **Corbo, M. – Valencia, X. – Raymond, R., et al.:** Subcutaneous administration of abatacept in patients with rheumatoid arthritis, pharmacokinetics, safety and immunogenicity. *Ann Rheum Dis*, 2009, 68, s. 574.
- 2 **Genovese, M. C. – Covarrubias, A. – Leon, G., et al.:** Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. *Arthritis Rheum*, 2011, 63, s. 2854–2864.
- 3 **Genovese, M. C. – Cobos, A. C. – Leon, G., et al.:** Subcutaneous (SC) abatacept (ABA) versus intravenous (IV) ABA in patients (pts) with rheumatoid arthritis: long-term data from the ACQUIRE (Abatacept Comparison of sub[QU]cutaneous versus intravenous in Inadequate Responders to methotrexatE) trial. *Arthritis Rheum*, 2011, 63, s. 402.
- 4 **Nash, P. – Nayiager, S. – Genovese, M., et al.:** Immunogenicity, safety and efficacy of abatacept administered subcutaneously with or

without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study. *Arthritis Care Res*, 2013, 65, s. 718–728.

- 5 **Keystone, E. C. – Kremer, J. M. – Russell, A., et al.:** Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study. *Ann Rheum Dis*, 2012, 71, s. 857–861.
- 6 **Kaine, J. – Gladstein, G. – Strusberg, I., et al.:** Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase IIIb ALLOW study). *Ann Rheum Dis*, 2012, 71, s. 38–44.
- 7 **Kaine, J. – Gladstein, G. – Strusberg, I., et al.:** Subcutaneous abatacept is effective and well tolerated, with low immunogenicity following temporary withdrawal and re-introduction in the ALLOW LTE. *Arthritis Rheum*, 2011, 63, s. 2190.
- 8 **Weinblatt, M. – Schiff, M. – Valente, R., et al.:** Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. *Arthritis Rheum*, 2012, 65, s. 28–38.
- 9 **Nash, P. – Ludivico, C. – Delaet, I., et al.:** Efficacy, safety and pharmacokinetics of subcutaneous abatacept in patients with rheumatoid arthritis, with or without an intravenous (IV) loading dose. *Arthritis Rheum*, 2011, 63, s. 404.
- 10 **Murthy, B. – Gao, L. – Vakkalagadda, B., et al.:** Clinical pharmacokinetics of subcutaneous abatacept in the presence or absence of an intravenous loading dose in patients with rheumatoid arthritis. *Ann Rheum Dis*, 2011, 70, s. 284.
- 11 **Schiff, M.:** Subcutaneous abatacept for the treatment of rheumatoid arthritis. *Rheumatology*, 2013, 52, s. 986–997.
- 12 **Alten, R. – Kaine, J. – Keystone, E. C., et al.:** Safety of subcutaneous abatacept in patients with rheumatoid arthritis (RA): integrated analysis of five clinical trials up to 4,5 years. *Ann Rheum Dis*, 2011, 63, s. 403.

Farmakologická léčba osteoporózy

MUDr. Petr Hrdý | MUDr. Pavel Novosad MEDIEKOS Labor, s. r. o., Osteocentrum, Zlín

- 1 **Lindsay, R. – Silverman, S. I. – Cooper, C., et al.:** Risk of new vertebral fracture in the year following a fracture. *JAMA*, 2001, 285, s. 320–323.
- 2 **van Groningen, L. – Opdenoordt, S. – van Sorge, A., et al.:** Cholecalciferol loading dose guideline for vitamin D-deficient adults. *Eur J Endocrinol*, 2010, 162, s. 805–811.
- 3 **Rossouw, J. E. – Anderson, G. L. – Prentice, R. L., et al.:** Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. *JAMA*, 2002, 288, s. 321–333.
- 4 **Cummings, S. R.:** LIFT study is discontinued. *BMJ*, 2006, 332, s. 667.
- 5 **Lufkin, E. G. – Wong, M. – Deal, C.:** The role of selective estrogen receptor modulators in the prevention and treatment of osteoporosis. *Rheum Dis Clin North Am*, 2001, 1, s. 163–185.
- 6 **Black, D. M. – Thompson, D. E. – Bauer, D. C., et al.:** Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. *J Clin Endocrinol Metab*, 2000, 85, s. 4118–4124.
- 7 **Reginster, J. – Minne, H. W. – Sorensen, O. H., et al.:** Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. *Osteoporos Int*, 2000, 11, s. 83–91.
- 8 **Reginster, J. Y. – Adami, S. – Lakatos, P., et al.:** Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. *Ann Rheum Dis*, 2006, 65, s. 654–661.
- 9 **Neer, R. M. – Arnaud, C. D. – Zanchetta, J. R., et al.:** Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. *N Engl J Med*, 2001, 344, s. 1434–1441.
- 10 **Chavassieux, P. – Brixen, K. – Zerbin, C., et al.:** *Osteoporosis Int*, 2011, 22 (dopl. 1), s. S104, abstrakt OC16.
- 11 **Meunier, P. J. – Roux, C. – Seeman, E., et al.:** The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. *N Engl J Med*, 2004, 350, s. 459–468.
- 12 **Reginster, J. Y. – Seeman, E. – De Vernejoul, M. C., et al.:** Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. *J Clin Endocrinol Metab*, 2005, 90, s. 2816–2822.
- 13 **Kanis, J. A. – Johansson, H. – Oden, A., et al.:** A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX®. *Osteoporos Int*, 2011, 22, s. 2347–2355.
- 14 **Ringe, J. D. – Dorst, A. – Farahmand, P.:** Efficacy of strontium ranelate on bone mineral density in men with osteoporosis. *Arzneimittelforschung*, 2010, 60, s. 267–272.
- 15 **Reginster, J. Y. – Pelousse, F. – Bruyere, O.:** Is there potential of strontium ranelate in the management of osteoarthritis? *Clin Pract*, 2013, 10, s. 201–207.
- 16 **Reginster, J. Y. – Badurski, J. – Bellamy, N., et al.:** Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. *Ann Rheum Dis*, 2013, 72, s. 179–186.
- 17 **Negri, A. L. – Spivacow, F. R.:** Healing of subtrochanteric atypical fractures after strontium ranelate treatment. *Clin Cases Miner Bone Metab*, 2012, 9, s. 166–169.
- 18 **Jorgensen, N. R. – Schwarz, P.:** Effects of anti-osteoporosis medications on fracture healing. *Curr Osteoporos Rep*, 2011, 9, s. 149–155.
- 19 **Cummings, S. – San Martin, J. – McClung, M., et al.:** FREEDOM Trial: Denosumab for prevention of fractures in postmenopausal women with osteoporosis. *N Engl J Med*, 2009, 361, s. 756–765.
- 20 **Heaney, R. P.:** The Vitamin D requirement in health and disease. *J Steroid Biochem Mol Biol*, 2005, 97, s. 13–19.

Denosumab v klinické praxi

MUDr. Olga Růžičková Revmatologický ústav, Praha

- 1 Hsu, H. – Lacey, D. L. – Dunstan, C. R., et al.: Tumor necrosis factor receptor family member RANK mediates osteoclasts differentiation and activation induced by osteoprotegerin ligand. *Proc Natl Acad Sci USA*, 1999, 96, s. 3540–3545.
- 2 Simonet, W. S. – Lacey, D. L. – Dunstan, C. R., et al.: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. *Cell*, 1997, 89, s. 309–319.
- 3 Tsuda, E. – Goto, M. – Mochizuki, S., et al.: Isolation of novel cytosine from human fibroblasts that specifically inhibit osteoclastogenesis. *Biochem Biophys Res Commun*, 1997, 234, s. 137–143.
- 4 Fata, J. E., et al.: The osteoclast differentiation factor osteoprotegerin ligand is essential for mammary gland development. *Cell*, 2000, 103, s. 41–50.
- 5 Nakagawa, N., et al.: RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. *Biochem Biophys Res Commun*, 1998, 253, s. 395–400.
- 6 Williamson, E. – Bilsborough, J. M. – J.L. Viney, J. L.: Regulation of mucosal dendritic cell function by receptor activator of NF-kappa B (RANK)/RANK ligand interactions: impact on tolerance induction. *J Immunol*, 2002, 169, s. 3606–3612.
- 7 Gonzalez-Suarez, E., et al.: RANK overexpression in transgenic mice with mouse mammary tumor virus promoter-controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial acini. *Mol Cell Biol*, 2007, 27, s. 1442–1454.
- 8 Genant, H. K. – Wu, C. Y. – van Kuijk, C. – Nevitt, M. C.: Vertebral fracture assessment using a semiquantitative technique. *J Bone Miner Res*, 1993, 8, s. 1137–1148.
- 9 Cummings, S. R. – San Martin, J. – McClung, M. R.: Denosumab for prevention of fractures in postmenopausal women with osteoporosis. *N Engl J Med*, 2009, 361, s. 756–765.
- 10 Hochberg, M. C. – Greenspan, S. – Wasnich, R. D. – Miller, P. – Thompson, D. E. – Ross, P. D.: Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. *J Clin Endocrinol Metab*, 2002, 87, s. 1586–1592.
- 11 Stein, C. M. – Ray, W. A.: The ethics of placebo in studies with fracture end points in osteoporosis. *N Engl J Med*, 2010, 363, s. 1367–1370.
- 12 Rosen, C. J. – Khola, S.: Placebo-controlled trials in osteoporosis—proceeding with caution. *N Engl J Med*, 2010, 363, s. 1365–1367.
- 13 Endocrinologie and Metabolic Drugs Advisory Committee Meeting Minutes, 2002. Dostupné z: <http://www.fda.gov/ohrms/dockets/ac/cder02.htm#EndocrinologicMetabolicDrugs>, vyhledáno 23. 5. 2011.
- 14 Bone, H. G. – Hosking, D. – Devogelaer, J. P. – Tucci, J. R. – Emkey, R. D. – Tonino, R. P. – Rodriguez-Portales, J. A. – Downs, R. W. – Gupta, J. – Santora, A. C. – Liberman, U. A.: Ten years' experience with alendronate for osteoporosis in postmenopausal women. *N Engl J Med*, 2004, 350, s. 1189–1199.
- 15 Papapoulos, S. – Chapurlat, R. – Libanati, C., et al.: Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension. *J Bone Miner Res*, 2012, 27, s. 694–701.
- 16 Roux, C. – Lippuner, K. – Bone, H. G., et al.: Denosumab treatment of postmenopausal women with osteoporosis for 7 years: Clinical fracture results from the first 4 years of the FREEDOM extension. *Ann Rheum Dis*, 2013, 72, s. 137.
- 17 Burgess, T. L. – Qian, Y. – Kaufman, S. – Ring, B. D. – Van, G. – Capparelli, C. – Kelley, M. – Hsu, H. – Boyle, W. I. – Dunstan, C. R. – Iliu, S. – Lacey, D. L.: The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. *J Cell Biol*, 1999, 145, s. 527–538.
- 18 Yasuda, I. I. – Shima, N. – Nakagawa, N. – Yamaguchi, K. – Kinosaki, M. – Mochizuki, S. – Tomoyasu, A. – Yano, K. – Goto, M. – Murakami, A. – Tsuda, E. – Morinaga, T. – Higashio, K. – Udagawa, N. – Takahashi, N. – Suda, T.: Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. *Proc Natl Acad Sci USA*, 1998, 95, s. 3597–3602.
- 19 Boyle, W. J. – Simonet, W. S. – Lacey, D. L.: Osteoclast differentiation and activation. *Nature*, 2003, 423, s. 337–342.
- 20 Miller, P. D. – Wagman, R. B. – Peacock, M. – Lewiecki, E. M. – Bolognese, M. A. – Weinstein, R. L. – Ding, B. – San Martin, J. – McClung, M. R.: Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. *J Clin Endocrinol Metab*, 2011, 96, s. 394–402.
- 21 Bone, H. G. – Hosking, D. – Devogelaer, J. P. – Tucci, J. R. – Emkey, R. D. – Tonino, R. P. – Rodriguez-Portales, J. A. – Downs, R. W. – Gupta, J. – Santora, A. C. – Liberman, U. A.: (2004) Ten years' experience with alendronate for osteoporosis in postmenopausal women. *N Engl J Med*, 2004, 350, s. 1189–1199.
- 22 Mellstrom, D. D. – Sorensen, O. H. – Goemaere, S. – Roux, C. – Johnson, T. D. – Chines, A. A.: Seven years of treatment with risedronate in women with postmenopausal osteoporosis. *Calcif Tissue Int*, 2004, 75, s. 462–468.
- 23 Macdonald, H. M. – Nishiyama, K. K. – Hanley, D. A. – Boyd, S. K.: Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis. *Osteoporos Int*, 2011, 22, s. 357–362.
- 24 Sato, M. – Westmore, M. – Ma, Y. L. – Schmidt, A. – Zeng, Q. Q. – Glass, E. V. – Vahle, J. – Brommage, R. – Jerome, C. P. – Turner, C. H.: Teriparatide [P ITI(1–34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity. *J Bone Miner Res*, 2004, 19, s. 623–629.
- 25 Brown, J. P. – Prince, R. L. – Deal, C. – Recker, R. R. – Kiel, D. P. – de Gregorio, L. H. – Hadji, P. – Ilotbauer, L. C. – Alvaro-Gracia, J. M. – Wang, H. – Austin, M. – Wagman, R. B. – Newmark, R. – Libanati, C. – San Martin, J. – Bone, H. G.: Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. *J Bone Miner Res*, 2009, 24, s. 153–161.
- 26 Genant, U. K. – Engelke, K. – Hanley, D. A. – Brown, J. P. – Omizo, M. – Bone, H. G. – Kivitz, A. J. – Fuerst, T. – Wang, H. – Austin, M. – Libanati, C.: Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. *Bone*, 2010, 47, s. 131–139.
- 27 Seeman, E. – Delmas, P. D. – Hanley, D. A. – Sellmeyer, D. – Cheung, A. M. – Shane, E. – Keams, A. – Thomas, T. – Boyd, S. K. – Boutroy, S. – Bogado, C. – Majumdar, S. – Fan, M. – Libanati, C. – Zanchetta, J.: Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. *J Bone Miner Res*, 2010, 25, s. 1886–1894.
- 28 Ominsky, M. S. – Jollette, J. – Smith, S. Y. – Vlasseros, F. – Samadifam, R. – Kostenuik, P. J.: Transition from alendronate to denosumab resulted in further reductions in local and systemic bone turnover parameters and reduced cortical porosity in ovariectomized cynomolgus monkeys [abstract 1216]. *J Bone Miner Res*, 2008, 23, s. S61.
- 29 McClung, M. R. – Lewiecki, E. M. – Geller, M. L., et al.: Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. *Osteoporos Int*, 2013, 24, s. 227–235.
- 30 Zebaze, J. R., et al.: Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross sectional study. *The*

- Lancet*, 2010, 375, s. 1729–1736.
- 31 Lindsay, R. – Scheele, W. H. – Neer, R. – Pohl, G. – Adami, S. – Mautalen, C. – Reginster, J. Y. – Stepan, J. J. – Myers, S. L. – Mitlak, B. H.: Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. *Arch Intern Med*, 2004, 164, s. 2024–2030.
 - 32 Prince, R. – Sipos, A. – Hossain, A. – Syversen, U. – Ish-Shalom, S. – Marcinowska, E. – Halse, J. – Lindsay, R. – Dalsky, G. P. – Mitlak, B. H.: Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. *J Bone Miner Res*, 2005, 20, s. 1507–1513.
 - 33 Miller, P. D.: Bisphosphonates: pharmacology and use in the treatment of osteoporosis. In: Marcus, R. F. D. – Nelson, D. A. – Rosen, C. J., editors: *Osteoporosis*. Burlington, M. A., Elsevier Academic Press, 2008, s. 1725–1742.
 - 34 Nancollas, G. H. – Tang, R. – Phipps, R. J. – Henneman, Z. – Guide, S. – Wu, W. – Mangood, A. – Russell, R. G. – Ebetino, F. H.: Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. *Bone*, 2006, 38, s. 617–627.
 - 35 Russell, R. G. – Watts, N. B. – Ebetino, F. H. – Rogers, M. J.: Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. *Osteoporos Int*, 2008, 19, s. 733–759.
 - 36 Watts, N. B. – Chines, A. – Olszynski, W. P. – McKeever, C. D. – McClung, M. R. – Zhou, X. – Grauer, A.: Fracture risk remains reduced one year after discontinuation of risedronate. *Osteoporos Int*, 2008, 19, s. 365–372.
 - 37 Black, D. M. – Schwartz, A. V. – Ensrud, K. E. – Cauley, J. A. – Levis, S. – Quandt, S. A. – Satterfield, S. – Wallace, R. B. – Bauer, D. C. – Palermo, L. – Wehren, L. E. – Lombardi, A. – Santora, A. C. – Cummings, S. R.: Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. *JAMA*, 2006, 296, s. 2927–2938.
 - 38 Black, D. M. – Reid, I. R. – Boonen, S. – Bucci-Rechtweg, C. – Cauley, J. A. – Cosman, F. – Cummings, S. R. – Hue, T. F. – Lippuner, K. – Lakatos, P. – Leung, P. C. – Man, Z. – Martinez, R. – Tan, M. – Ruzicky, M. E. – Su, G. – Eastell, R.: The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). *J Bone Miner Res*, 2012, 27, s. 243–254.
 - 39 Bone, H. G. – Bolognese, M. A. – Yuen, C. K. – Kendler, D. L. – Miller, P. D. – Yang, Y. C. – Grazette, L. – San Martin, J. – Gallagher, J. C.: Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. *J Clin Endocrinol Metab*, 2011, 96, s. 972–980.
 - 40 Brown, J. P. – Dempster, D. W. – Ding, B. – Dent-Acosta, R. – San Martin, J. – Grauer, A. – Wagman, R. B. – Zanchetta, J.: Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy study. *J Bone Miner Res*, 2011, 26, s. 2737–2744.
 - 41 Miller, P. D. – Bolognese, M. A. – Lewiecki, E. M. – McClung, M. R. – Ding, B. – Austin, M. – Liu, Y. – San Martin, J.: Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. *Bone*, 2008, 43, s. 222–229.
 - 42 Brown, J. P. – Roux, C. – Topping, O., et al.: Discontinuation of denosumab and associated fracture incidence: Analysis from the fracture reduction evaluation of denosumab in osteoporosis every 6 months (FREEDOM). *J Bone Miner Res*, 2013, 28, s. 746–752.
 - 43 Shi, N. – Foley, K. – Lenhart, G. – Badamgarav, E.: Direct health-care costs of hip, vertebral, and non-hip, non-vertebral fractures. *Bone*, 2009, 45, s. 1084–1090, Epub 5. 8. 2009.
 - 44 Blume, S. W. – Curtis, J. R.: Medical costs of osteoporosis in the elderly Medicare population. *Osteoporos Int*, 2011, 22, s. 1835–1844, Epub 17. 12. 2010.
 - 45 Pike, C. – Birnbaum, H. G. – Schiller, M. – Sharma, H. – Burge, R. – Edgell, E. T.: Direct and indirect costs of non vertebral fracture patients with osteoporosis in the US. *Pharmacoeconomics*, 2010, 28, s. 395–409, doi: 10.2165/11531040-000000000 00000.
 - 46 Center, J. R. – Bliuc, D. – Nguyen, T. V. – Eisman, J. A.: Risk of subsequent fracture after low trauma fracture in men and women. *JAMA*, 2007, 297, s. 387–394.
 - 47 van Geel, T. A. – van Helden, S. – Geusens, P. P. – Winkens, B. – Dinant, G. J.: Clinical subsequent fractures cluster in time after first fractures. *Ann Rheum Dis*, 2009, 68, s. 99–102, Epub 3. 8. 2008.
 - 48 van Geel, T. A. – Huntjens, K. M. – van den Bergh, J. P. – Dinant, G. J. – Geusens, P. P.: Timing of subsequent fractures after an initial fracture. *Curr Osteoporos Rep*, 2010, 8, s. 118–122.
 - 49 Colón-Emeric, C. – Kuchibhatla, M. – Pieper, C. – Hawkes, W. – Fredman, L. – Magaziner, J. – Zimmerman, S. – Lyles, K. W.: The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies. *Osteoporos Int*, 2003, 14, s. 879–883, Epub 3. 10. 2003.
 - 50 Klotzbuecher, C. M. – Ross, P. D. – Landsman, P. B. – Abbott, T. A., 3rd – Berger, M.: Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. *J Bone Miner Res*, 2000, 15, s. 721–739.
 - 51 Pountos, I. – Georgouli, T. – Blokhuis, T. J. – Pape, H. C. – Giannoudis, P. V.: Pharmacological agents and impairment of fracture healing: what is the evidence? *Injury*, 2008, 39, s. 384–94, Epub 7. 3. 2008.
 - 52 Recker, R. R. – Lewiecki, E. M. – Miller, P. D. – Reiffel, J.: Safety of bisphosphonates in the treatment of osteoporosis. *Am J Med*, 2009, 122, s. S22–S32.
 - 53 Odvina, C. V. – Zerwekh, J. E. – Rao, D. S. – Maalouf, N. – Gottschalk, F. A. – Pak, C. Y.: Severely suppressed bone turnover: a potential complication of alendronate therapy. *J Clin Endocrinol Metab*, 2005, 90, s. 1294–1301, Epub 14. 12. 2004.
 - 54 Ing-Lorenzini, K. – Desmeules, J. – Plachta, O. – Suva, D. – Dayer, P. – Peter, R.: Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. *Drug Saf*, 2009, 32, s. 775–785, doi: 10.2165/00002018-200932090 00002.
 - 55 Lyles, K. W. – Colón-Emeric, C. S. – Magaziner, J. S. – Adachi, J. D. – Pieper, C. F. – Mautalen, C. – Hyldstrup, L. – Recknor, C. – Nordsletten, L. – Moore, K. A. – Lavecchia, C. – Zhang, J. – Mesenbrink, P. – Hodgson, P. K. – Abrams, K. – Orloff, J. J. – Horowitz, Z. – Erikssen, E. F. – Boomem, S.: HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. *N Engl J Med*, 2007, 357, s. 1799–809, Epub 17. 9. 2007.
 - 56 van der Poest Clement, E. – Patka, P. – Vandormael, K. – Haarman, H. – Lips, P.: The effect of alendronate on bone mass after distal forearm fracture. *J Bone Miner Res*, 2000, 15, s. 586–593.
 - 57 Beupre, L. A. – Morrish, D. W. – Hanley, D. A. – Maksymowich, W. P. – Bell, N. R. – Juby, A. G. – Majumdar, S. R.: Oral bisphosphonates are associated with reduced mortality after hip fracture. *Osteoporos Int*, 2011, 22, s. 983–991, Epub 4. 11. 2010.
 - 58 Adachi, J. D. – Lyles, K. W. – Colón Emeric, C. S. – Boonen, S. – Pieper, C. F. – Mautalen, C. – Hyldstrup, L. – Recknor, C. – Nordsletten, L. – Moore, K. A. – Bucci Rechtweg, C. – Su, G. – Eriksen, E. F. – Magaziner, J. S.: Zoledronic acid results in better health related quality of life following hip fracture: the HORIZON-Recurrent Fracture Trial. *Osteoporos Int*, 2011, 22, s. 2539–2549, Epub 20. 1. 2011.
 - 59 Adami, S. – Libanati, C. – Boonen, S., et al.: Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing. *J Bone Joint Surg Am*, 2012, 94, s. 2113–2119.
 - 60 Flick, L. M. – Weaver, J. M. – Ulrich-Vinther, M. – Abuzzahab, F. – Zhang, X. – Doufalo, W. C. – Anderson, D. – O’Keefe, R. J. – Schwarz, E. M.: Effects of receptor activator of NRoppaB (RANK) signaling blockade on fracture healing. *J Orthop Res*, 2003, 21, s. 676–684.
 - 61 Ulrich-Vinther, M. – Andreessen, T. T.: Osteoprotegerin treatment impairs remodeling and apparent material properties of callus tissue without influencing structural fracture strength. *Calcif Tissue Int*, 2005, 76, s. 280–286, Epub 11. 4. 2005.
 - 62 Boyle, W. J., et al.: *Nature*. 2003, 423, s. 337–342.
 - 63 Kostenuik, P. J., et al.: *Curr Pharm Des*. 2001, 7, s. 613–635.

Stručný přehled terapie bolesti u revmatických chorob

MUDr. Hana Ciferská, Ph.D. | MUDr. Olga Šléglová Revmatologický ústav, Praha

- 1 Chiaretti, A. – Pierri, F. – Valentini, P., et al.: Current practice and recent advances in pediatric pain management. *Eur Rev Med Pharmacol Sci*, 2013, dopl. 1, s. 112–126.
- 2 Rokyta, R., et al.: *Bolest*. Praha, Tigris, 2012.
- 3 Šléglová, O. – Pavelka, K.: Bolest u revmatických onemocnění a možnosti využití opioidů v její léčbě. *Ortopedie*, 2007, 3, s. 115–120.
- 4 Pavelka, K., et al.: *Revmatologie*. Praha, Maxdorf, 2012.
- 5 Albe-Fessard, D., et al.: *Bolest – mechanismy a základ léčby*. Praha, Grada, 1998.
- 6 Whittle, S. L. – Colebatch, A. N. – Buchbinder, R., et al.: Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative. *Rheumatology (Oxford)*, 2012, 51 (8), s. 1416–1425.
- 7 Scascighini, L. – Toma, V. – Dober-Spielmann, S. – Sprott, H.: Multidisciplinary treatment for chronic pain: a systematic review of interventions and outcomes. *Rheumatology (Oxford)*, 2008, 47 (5), s. 670–678.
- 8 *Farmakoterapie bolesti. Doporučený postup pro všeobecné praktické lékaře z roku 2004*.
- 9 Cruccu, G. – Truini, A.: Tools for assessing neuropathic pain. *PLoS Med*, 2009, 7, 6 (4), s. e1000045.
- 10 Svendsen, K. B. – Jensen, T. S. – Hansen, H. J., et al.: Sensory function and quality of life in patients with multiple sclerosis and pain. *Pain*, 2005, 114, s. 473–448.
- 11 Morley, S.: Psychology of pain. *Br J Anaesth*, 2008, 101, s. 25–31.
- 12 Aletaha, D. – Neogi, T. – Silman, A. J., et al.: Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis Rheum*, 2010, 62 (9), s. 2569–2581.
- 13 Farheen, K. – Agarwal, S. K.: Assessment of disease activity and treatment outcomes in rheumatoid arthritis. *J Manag Care Pharm*, 2011, 17 (9 dopl. B), s. S09–S13.
- 14 Perrot, S. – Javier, R. M. – Marty, M., et al.: CEDR (Cercle d'Etude de la Douleur en Rhumatologie France), French Rheumatological Society, Pain Study Section. Is there any evidence to support the use of anti-depressants in painful rheumatological conditions? Systematic review of pharmacological and clinical studies. *Rheumatology (Oxford)*, 2008, 47 (8), s. 1117–1123.
- 15 Saag, K. G. – Teng, G. G. – Patkar, N. M., et al.: American College of Rheumatology, recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. *Arthritis Rheum*, 2008, 59 (6), s. 762–784.
- 16 Rudwaleit, M. – van der Heijde, D. – Landewé, R., et al.: The Assessment of Spondylo Arthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. *Ann Rheum Dis*, 2011, 70, s. 25–31.
- 17 Sieper, J. – van der Heijde, D. – Landewé, R., et al.: New criteria for inflammatory backpain in patients with chronic backpain: a real patient exercise by experts from the Assessment of Spondylo Arthritis International Society (ASAS). *Ann Rheum Dis*, 2009, 68, s. 784–788.
- 18 Zhang, W. – Doherty, M. – Pascual, E., et al.: EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCSIT). *Ann Rheum Dis*, 2006, 65, 10, s. 1301–1311.
- 19 Pavelka, K. – Trč, T. – Karpát, K., et al.: The efficacy and safety of diclofenac in the treatment of painful osteoarthritis of the knee. A randomized, multicenter, double-blind, placebo-controlled study with primary endpoints at two months after the end of three-month treatment period. *Arthritis Rheumatism*, 2007, 56, s. 4055–4064.
- 20 Brummett, C. M. – Clauw, D. J.: Fibromyalgia: a primer for the anesthesia community. *Curr Opin Anaesthesiol*, 2011, 24 (5), s. 532–539.
- 21 Solanki, D. R. – Koyalagunta, D. – Shah, R. V., et al.: Monitoring opioid adherence in chronic pain patients: assessment of risk of substance misuse. *Pain Physician*, 2011, 14 (2), s. E119–E131.
- 22 Kršiák, M. – Doležal, T. – Lejčko, J.: Neopioidní analgetika. *Bolest*, 2006, s. 106–115.
- 23 Boers, M. – Tangelder, M. J. D. – van Ingen, H., et al.: The rate of NSAID-induced endoscopic ulcers increases linearly but not exponentially with age: a pooled analysis of 12 randomised trials. *Ann Rheum Dis*, 2007, 66, 3, s. 417–418.
- 24 Angel Lanás, A. – Tornero, J. – Zamorano, L. J.: Extended report: Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study. *Ann Rheum Dis*, 2010, 69, 8, s. 1453–1458.
- 25 Fields, H. – Basbaum, A. I. – Heinricher, M. M.: Central nervous system mechanisms of pain modulation. In: McMahon, S. – Koltzenburg, M. (eds.): *Textbook of Pain*. New York, Churchill Livingstone, 2006.
- 26 O'Neil, C. K. – Hanlon, J. T. – Marcum, Z. A.: Adverse effects of analgesics commonly used by older adults with osteoarthritis: focus on non-opioid and opioid analgesics. *Am J Geriatr Pharmacother*, 2012, 10 (6), s. 331–342.
- 27 Berland, D. – Rodgers, P.: Rational use of opioids for management of chronic nonterminal pain. *Am Fam Physician*, 2012, 1, 86 (3), s. 252–258.
- 28 Makris, U. E. – Kohler, M. J. – Fraenkel, L.: Adverse effects of topical nonsteroid anti-inflammatory drugs in older adults with osteoarthritis: a systematic literature review. *J Rheumatol*, 2010, 37 (6), s. 1236–1243.
- 29 Dickson, D. J.: A double-blind evaluation of topical piroxicam gel with oral ibuprofen in osteoarthritis of the knee. *Curr Ther Res Clin E*, 1991, 49, s. 199–207.
- 30 Andrews, P. A. – Sampson, S. A.: Topical non-steroidal drugs are systemically absorbed and may cause renal disease. *Nephrol Dial Transpl*, 1999, 14, s. 187–189.
- 31 Mitchell, K. – Kaul, M. – Clowse, M. E.: The management of rheumatic diseases in pregnancy. *Scand J Rheumatol*, 2010, 39 (2), s. 99–108.

Imunogenicita inhibitorů TNF α v léčbě revmatoidní artritidy

MUDr. Rudolf Horváth, Ph.D.

Ústav imunologie 2. LF UK a FN Motol, Praha, Revmatologický ústav, Praha

- 1 **Weinblatt, M. E., et al.:** Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. *Arthritis Rheum*, 2003, 48, s. 35–45.
- 2 **Baert, F., et al.:** Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. *N Engl J Med*, 2003, 348, s. 601–608.
- 3 **Pascual-Salcedo, D., et al.:** Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. *Rheumatology (Oxford)*, 2011, 50, s. 1445–1452.
- 4 **Wolbink, G. J., et al.:** Development of anti-infliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. *Arthritis Rheum*, 2006, 54, s. 711–715.
- 5 **Bendtsen, K., et al.:** Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. *Arthritis Rheum*, 2006, 54, s. 3782–3789.
- 6 **Svenson, M. – Geborek, P. – Saxne, T. – Bendtsen, K.:** Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. *Rheumatology (Oxford)*, 2007, 46, s. 1828–1834.
- 7 **Jamnitski, A., et al.:** The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. *Ann Rheum Dis*, 2011, 70, s. 284–288.
- 8 **van de Putte, L. B., et al.:** Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. *Ann Rheum Dis*, 2004, 63, s. 508–516.
- 9 **Miyasaka, N.:** Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. *Mod Rheumatol*, 2008, 18, s. 252–262.
- 10 **Bartelds, G. M., et al.:** Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. *JAMA*, 2011, 305, s. 1460–1468.
- 11 **Kriekkaert, C. – Rispeens, T. – Wolbink, G.:** Immunogenicity of biological therapeutics: from assay to patient. *Curr Opin Rheumatol*, 2012, 24, s. 306–311.
- 12 **Petitpain, N., et al.:** Arterial and venous thromboembolic events during anti-TNF therapy: a study of 85 spontaneous reports in the period 2000–2006. *Biomed Mater Eng*, 2009, 19, s. 355–364.
- 13 **Makol, A. – Grover, M. – Guggenheim, C. – Hassouna, H.:** Etanercept and venous thromboembolism: a case series. *J Med Case Rep*, 2010, 4, s. 12.
- 14 **Korswagen, L. A., et al.:** Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study. *Arthritis Rheum*, 2011, 63, s. 877–883.
- 15 **Dore, R. K., et al.:** The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. *Clin Exp Rheumatol*, 2007, 25, s. 40–46.
- 16 **Jamnitski, A., et al.:** Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. *Ann Rheum Dis*, 2012, 71, s. 88–91.
- 17 **Anderson, P. J.:** Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. *Semin Arthritis Rheum*, 2005, 34, s. 19–22.
- 18 **Jacobi, A. M., et al.:** Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. *Arthritis Rheum*, 2008, 58, s. 1762–1773.
- 19 **Fleischmann, R., et al.:** Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. *Ann Rheum Dis*, 2009, 68, s. 805–811.
- 20 **Smolen, J., et al.:** Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. *Ann Rheum Dis*, 2009, 68, s. 797–804.
- 21 **Vennegoor, A., et al.:** Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. *Mult Scler*, 2013, 19, s. 593–600.
- 22 **Rathanaswami, P., et al.:** Demonstration of an in vivo generated subpicomolar affinity fully human monoclonal antibody to interleukin-8. *Biochem Biophys Res Commun*, 2005, 334, s. 1004–1013.
- 23 **Bray, G. L., et al.:** A multicenter study of recombinant factor VIII (recombinant): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. *Blood*, 1994, 83, s. 2428–2435.
- 24 **Lusher, J. M. – Arkin, S. – Abildgaard, C. F. – Schwartz, R. S.:** Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. *N Engl J Med*, 1993, 328, s. 453–459.
- 25 **Antonelli, G., et al.:** Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha2 therapy. *Clin Exp Immunol*, 1996, 104, s. 384–387.
- 26 **Antonelli, G.:** Neutralising antibodies against interferon beta in multiple sclerosis. *Lancet*, 2004, 363, s. 168–169.
- 27 **Aarden, L. – Ruuls, S. R. – Wolbink, G.:** Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. *Curr Opin Immunol*, 2008, 20, s. 431–435.
- 28 **Chirmule, N. – Jawa, V. – Meibohm, B.:** Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. *AAPS J*, 2012, 14, s. 296–302.
- 29 **Koren, E., et al.:** Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. *J Immunol Methods*, 2008, 333, s. 1–9.
- 30 **Hart, M. H., et al.:** Differential effect of drug interference in immunogenicity assays. *J Immunol Methods*, 2011, 372, s. 196–203.
- 31 **Wang, Y. M. – Fang, L. – Zhou, L. – Wang, J. – Ahn, H. Y.:** A survey of applications of biological products for drug interference of immunogenicity assays. *Pharm Res*, 2012, 29, s. 3384–3392.
- 32 **van Schouwenburg, P. A., et al.:** A novel method for the detection of antibodies to adalimumab in the presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patients. *J Immunol Methods*, 2010, 362, s. 82–88.
- 33 **Bartelds, G. M., et al.:** Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. *Ann Rheum Dis*, 2010, 69, s. 817–821.
- 34 **Kosmac, M., et al.:** Exploring the binding sites of anti-infliximab antibodies in pediatric patients with rheumatic diseases treated with infliximab. *Pediatr Res*, 2011, 69, s. 243–248.
- 35 **van Schouwenburg, P. A., et al.:** IgG₄ production against adalimumab during long term treatment of RA patients. *J Clin Immunol*, 2012, 32, s. 1000–1006.
- 36 **Baker, M. P. – Reynolds, H. M. – Lumericis, B. – Bryson, C. J.:** Immunogenicity of protein therapeutics: The key causes, consequences and challenges. *Self Nonself*, 2010, 1, s. 314–322.
- 37 **Ben-Horin, S., et al.:** The immunogenic part of infliximab is the F(ab)₂, but measuring antibodies to the intact infliximab molecule is more clinically useful. *Gut*, 2011, 60, 41–48.

- 38 van Schouwenburg, P. A., et al.: Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. *Ann Rheum Dis*, 2013, 72, s. 104–109.
- 39 Lobo, E. D. – Hansen, R. J. – Balthasar, J. P.: Antibody pharmacokinetics and pharmacodynamics. *J Pharm Sci*, 2004, 93, s. 2645–2668.
- 40 Moreland, L. W., et al.: Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. *Ann Intern Med*, 1999, 130, s. 478–486.
- 41 Weinblatt, M. E., et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. *N Engl J Med*, 1999, 340, s. 253–259.
- 42 Rojas, J. R., et al.: Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. *J Pharmacol Exp Ther*, 2005, 313, s. 578–585.
- 43 van der Laken, C. J., et al.: Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. *Ann Rheum Dis*, 2007, 66, s. 253–256.
- 44 Clark, M.: Antibody humanization: a case of the 'Emperor's new clothes'? *Immunol Today*, 2000, 21, s. 397–402.
- 45 Bartelds, G. M., et al.: Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms. *Arthritis Rheum*, 2009, 60, s. 2541–2542.
- 46 Fakhrazadeh, S. S. – Kazazian, H. H., Jr.: Correlation between factor VIII genotype and inhibitor development in hemophilia A. *Semin Thromb Hemost*, 2000, 26, s. 167–171.
- 47 Maini, R. N., et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. *Arthritis Rheum*, 1998, 41, s. 1552–1563.
- 48 Oldenburg, J. – Schwaab, R. – Brackmann, H. H.: Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn Protocol': predictive parameter for therapy duration and outcome. *Vox Sang*, 1999, 77, s. 49–54.
- 49 Schellekens, H.: Factors influencing the immunogenicity of therapeutic proteins. *Nephrol Dial Transplant*, 2005, 20, s. vi3–9.
- 50 Porter, S.: Human immune response to recombinant human proteins. *J Pharm Sci*, 2001, 90, s. 1–11.
- 51 Konrad, M. W. – Childs, A. L. – Merigan, T. C. – Borden, E. C.: Assessment of the antigenic response in humans to a recombinant mutant interferon beta. *J Clin Immunol*, 1987, 7, s. 365–375.
- 52 Genovese, M. C., et al.: Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. *Arthritis Rheum*, 2011, 63, s. 2854–2864.
- 53 Somerfield, J., et al.: A novel strategy to reduce the immunogenicity of biological therapies. *J Immunol*, 2010, 185, s. 763–768.
- 54 Kohno, T. – Tam, L. T. – Stevens, S. R. – Louie, J. S.: Binding characteristics of tumor necrosis factor receptor—Fc fusion proteins vs anti-tumor necrosis factor mAbs. *J Invest Dermatol Symp Proc*, 2007, 12, s. 5–8.
- 55 Kim, M. S., et al.: Comparative analyses of complex formation and binding sites between human tumor necrosis factor-alpha and its three antagonists elucidate their different neutralizing mechanisms. *J Mol Biol*, 2007, 374, s. 1374–1388.
- 56 Jones, T. D., et al.: Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII. *J Thromb Haemost*, 2005, 3, s. 991–1000.
- 57 Moise, L., et al.: Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo. *Clin Immunol*, 2012, 142, s. 320–331.
- 58 Schellekens, H.: Immunogenicity of therapeutic proteins. *Nephrol Dial Transplant*, 2003, 18, s. 1257–1259.
- 59 Fulcher, C. A. – de Graaf Mahoney, S. – Roberts, J. R. – Kasper, C. K. – Zimmerman, T. S.: Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments. *Proc Natl Acad Sci USA*, 1985, 82, s. 7728–7732.
- 60 Scandella, D., et al.: Epitope specificity and functional characterization of factor VIII inhibitors. *Adv Exp Med Biol*, 1995, 386, s. 47–63.
- 61 Parker, E. T. – Healey, J. F. – Barrow, R. T. – Craddock, H. N. – Lollar, P.: Reduction of the inhibitory antibody response to human factor VIII in hemophilia A mice by mutagenesis of the A2 domain B-cell epitope. *Blood*, 2004, 104, s. 704–710.
- 62 Rosendaal, F. R., et al.: A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group. *Blood*, 1993, 81, s. 2180–2186.
- 63 Locatelli, F. – Del Vecchio, L. – Pozzoni, P.: Pure red-cell aplasia "epidemic"—mystery completely revealed? *Perit Dial Int*, 2007, 27, s. S303–307.
- 64 Jefferis, R.: Glycosylation of recombinant antibody therapeutics. *Bio-technol Prog*, 2005, 21, s. 11–16.
- 65 Finckh, A., et al.: Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients. *Joint Bone Spine*, 2010, 77, s. 313–318.
- 66 Hoshino, M. – Yoshio, T. – Onishi, S. – Minota, S.: Influence of antibodies against infliximab and etanercept on the treatment effectiveness of these agents in Japanese patients with rheumatoid arthritis. *Mod Rheumatol*, 2012, 22, s. 532–540.
- 67 Haraoui, B. – Cameron, L. – Ouellet, M. – White, B.: Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. *J Rheumatol*, 2006, 33, s. 31–36.
- 68 Bartelds, G. M., et al.: Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. *Ann Rheum Dis*, 2007, 66, s. 921–926.
- 69 Keystone, E., et al.: Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. *Arthritis Rheum*, 2008, 58, s. 3319–3329.
- 70 Choy, E., et al.: Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. *Rheumatology* (Oxford), 2012, 51, s. 1226–1234.
- 71 Zhuang, Y., et al.: Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study. *Clin Ther*, 2012, 34, s. 77–90.
- 72 Keystone, E. C., et al.: Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. *Ann Rheum Dis*, 2009, 68, s. 789–796.
- 73 Klareskog, L., et al.: Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis. *Clin Exp Rheumatol*, 2011, 29, s. 238–247.
- 74 Keystone, E. C., et al.: Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum*, 2004, 50, s. 353–363.
- 75 Kriekkaert, C., et al.: Evaluating the cost-effectiveness of personalized treatment with adalimumab using serum drug level and anti-adalimumab antibodies in rheumatoid arthritis patients. *Poster OP0149*, EULAR 2012.
- 76 van Vollenhoven, R. F.: Unresolved issues in biologic therapy for rheumatoid arthritis. *Nat Rev Rheumatol*, 2011, 7, s. 205–215.
- 77 van Schouwenburg, P. A., et al.: Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. *Nat Rev Rheumatol*, 2013, 9, s. 164–172.

Kalcium a vitamin D v prevenci a léčbě glukokortikoidy indukované osteoporózy

MUDr. Olga Růžičková Revmatologický ústav, Praha

- 1 Van Staa, T. P. – Leufkens, H. G. – Abenhaim, L. – Zhang, B. – Cooper, C.: Use of oral corticosteroids and risk of fractures. *J Bone Miner Res*, 2000, 15, s. 993–1000.
- 2 Shaker, J. L. – Lukert, B. P.: Osteoporosis associated with excess glucocorticoids. *Endocrinol Metab Clin North Am*, 2005, 34, s. 341–356.
- 3 Canalis, E.: Mechanism of glucocorticoid-induced osteoporosis. *Curr Opin Rheumatol*, 2003, 15, s. 454–457.
- 4 Geusens, P. – van Brussel, M. S. – Lems, W. F.: Osteoporosis and fracture risk: pathogenesis, epidemiology, clinical aspects and diagnosis. *EULAR Compendium on Rheumatic Diseases*, 2009.
- 5 Štěpán, J.: Osteoporóza a metabolická onemocnění skeletu. In: Pavelka, K., et al.: *Revmatologie*. Praha, Maxdorfjessenius, 2012, s. 483–552.
- 6 Walsh, L. J. – Wong, C. A. – Osborne, J., et al.: Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. *Thorax*, 2001, 56, s. 279–284.
- 7 Růžičková, O. – Bayer, M. – Pavelka, K. – Palička, V.: Doporučení pro prevenci a léčbu glukokortikoidy indukované osteoporózy u pacientů s revmatickým onemocněním (Společné stanovisko České revmatologické společnosti a Společnosti pro metabolická onemocnění skeletu). *Čes Revmatol*, 2004, 12, s. 163–174.
- 8 American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. *Arthritis Rheum*, 2001, 44, s. 1496–1503.
- 9 Curtis, J. R. – Westfall, A. O. – Allison, J. J., et al.: Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. *Arthritis Rheum*, 2005, 52, s. 2485–2494.
- 10 Matkovic, V. – Heaney, R. P.: Calcium balance during human growth: Evidence for threshold behavior. *Am J Clin Nutr*, 1992, 55, s. 992–996.
- 11 Dawson-Hughes, B. – Dallal, G. E. – Krall, E. A. – Sadowski, L. – Sahyoun, N. – Tannen-Baum, S.: A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. *N Engl J Med*, 1990, 323, s. 878–883.
- 12 Reid, I. R. – Ibbertson, H. K.: Calcium supplements in the prevention of steroid-induced osteoporosis. *Amer J Clin Nutr*, 1986, 44, s. 287–290.
- 13 Sambrook, P. – Birmingham, J. – Kelly, P. – Kempler, S. – Nguyen, T. – Pocock, N. – Eisman, J.: Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol and calcitonin. *N Engl J Med*, 1995, 328, s. 1747–1752.
- 14 Adachi, J. D. – Bensen, W. G. – Brown, J., et al.: Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. *N Engl J Med*, 1997, 337, s. 382–387.
- 15 Roux, C. – Oriente, P. – Laan, R., et al.: Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. *J Clin Endocrinol Metab*, 1998, 83, s. 1128–1133.
- 16 Cohen, S. – Levy, R. M. – Keller, M., et al.: Risedronate therapy prevents corticosteroid-induced bone loss. A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. *Arthritis Rheum*, 1999, 42, s. 2309–2318.
- 17 Hahn, T. J. – Hahn, B. H.: Osteopenia in subjects with rheumatic diseases: Principles of diagnosis and therapy. *Semin Arthritis Rheum*, 1997, 6, s. 65–88.
- 18 Hahn, T. J. – Halstead, L. R. – Teitelbaum, S. L. – Hahn, B. H.: Altered mineral metabolism in glucocorticoid-induced osteopenia: Effect of 25-hydroxyvitamin D administration. *J Clin Invest*, 1979, 64, s. 655–665.
- 19 Lane, N. E. – Genant, H. K. – Kiney, J. H. – Englemann, E.: Effect of intermittent cyclic etidronate (ICT) therapy for glucocorticoid-induced osteoporosis in rheumatoid arthritis (RA): Interim analysis. *J Bone Miner Res*, 1993, 8, s. S262.
- 20 Pitt, P. – Li, F. – Macitohs, C.: A double-blind placebo-controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term corticosteroid treatment. *J Bone Miner Res*, 1997, 12, s. S510.
- 21 Poubelle, P. E. – Adachi, J. D. – Hawkins, F.: Alendronate increases bone mineral density in patients on glucocorticoid therapy: Results of the multinational study. *Arthritis Rheum*, 1997, 40, s. S327.
- 22 Adachi, J. D. – Ioannidis, G.: Calcium and vitamin D therapy in corticosteroid-induced bone loss: What is the evidence? *Calcif Tissue Int*, 1999, 65, s. 332–336.
- 23 Lund, B. – Andersen, R. B. – Friis, T. – Hjorth, L. – Jorgensen, F. S. – Norman, A. W. – Sorensen, O. H.: Effect of 1-alpha-hydroxy vitamin D3 and 1,25-dihydroxy vitamin D3 on intestine and bone in glucocorticoid-treated patients. *Clin Endocrinol*, 1977, 7, s. 177–181.
- 24 Ringe, J. D.: Active vitamin D metabolites in glucocorticoid-induced osteoporosis. *Calcif Tissue Int*, 1997, 60, s. 124–127.
- 25 Tsurukami, H. – Nakamura, T. – Suzuki, I. K. – Sato, K. – Higuchi, Y. – Nishii, Y.: A novel synthetic vitamin D analogue, 2β-(3-hydroxypropoxy) 1,25-dihydroxyvitamin D3 (ED-71), increases bone mass by stimulating the bone formation in normal and ovariectomized rats. *Calcif Tissue Int*, 1994, 54, s. 142–149.
- 26 Shiraiishi, A. – Takeda, S. – Masaki, T., et al.: Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: Distinct actions from estrogen. *J Bone Miner Res*, 2000, 15, s. 770–779.
- 27 Dykman, T. R. – Haralson, K. M. – Gluck, O. S., et al.: Effect of oral 1,25-dihydroxyvitamin D and calcium on glucocorticoid-induced osteopenia in patients with rheumatic diseases. *Arthritis Rheum*, 1984, 27, s. 1336–1343.
- 28 Neuhaus, R. – Lohmann, R. – Platz, K. P., et al.: Treatment of osteoporosis after liver transplantation. *Transplant Proc*, 1995, 27, s. 1226–1227.
- 29 Sambrook, P. – Marshall, G. – Henderson, K. – Keogh, A. – MacDonald, P. – Spratt, P.: Effect of calcitriol in the prevention of bone loss after cardiac or lung transplantation. *J Bone Miner Res*, 1997, 12, s. S400.
- 30 Graf, H. – Tummvoll, H. K. – Kovarik, J. – Bergmann, H.: Aktive Vitamin-D-Metabolite in der Therapie der Cortisonosteoporose. *Wiener Klin Wschr*, 1980, 92, s. 776–777.
- 31 Braun, J. J. – Birkenhager-Frenkel, D. H. – Rietveld, A. H. – Juttman, J. R. – Visser, T. J. – Birkenhager, J. C.: Influence of alpha-(OH) D3 administration on bone and bone mineral metabolism in patients on chronic glucocorticoid treatment; A double blind controlled study. *Clin Endocrinol*, 1983, 18, s. 265–273.
- 32 Saadtop-Bohr, H. H.: Alfacalcidol in prednisone treatment—A controlled study of effect on bone mineral content in lumbar spine, femoral neck and shaft. *Calcif Tissue Int*, 1986, 39, s. A58.
- 33 Verstraeten, A. – Dequerki, J. – Nijs, J. – Geusens, P.: Prevention of postmenopausal bone loss in rheumatoid arthritis patients. A two-year prospective study. *Clin Exp Rheumatol*, 1989, 7, s. 351–358.
- 34 Y Am Ada, H.: Long-term effect of alpha-hydroxy vitamin D, calcium and thiazide administration on glucocorticoid-induced osteoporosis. *Nippon Naibunpi gakkai zasshi*, 1989, 65, s. 603–614.
- 35 Van Cleemput, J. – Daenen, W. – Geusens, P. – Dequerker, J. – Van de Werf, F. – Vanhaecke, J.: Prevention of bone loss in cardiac transplant recipients. *Transplantation*, 1996, 61, s. 1495–1499.
- 36 Lakatos, P. – Kiss, L. – Horvath, C. – Takacs, I. – Foldes, J. – Bossanyi, A.: Prevention of corticosteroid-induced osteoporosis with alphacalcidol. *Legge Artis Medicinae*, 1996, 6, s. 624–629.
- 37 Reginster, J. Y. – Kuntz, D. – Verdickt, W. – Wouters, M. – Guilevi, L. – Menkes, C. J. – Nielsen, K.: Prophylactic use of alfacalcidol in

- corticosteroid-induced osteoporosis. *Osteoporos Int*, 1999, 9, s. 75–81.
- 38 **Chapuy, M. C. – Arlot, M. E. – Duboef, F., et al.:** Vitamin D3 and calcium to prevent hip fractures in elderly women. *N Engl J Med*, 1992, 327, s. 1637–1642.
- 39 **Dawson-Huges, B. – Harris, S. S. – Krall, E. A. – Dallal, G. E.:** Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age and older. *N Engl J Med*, 1997, 337, s. 670–676.
- 40 **Francis, R. M. – Boyle, I. T. – Moniz, C., et al.:** A comparison of the effects of alfacalcidol treatment and vitamin D2 supplementation on calcium absorption in elderly women with vertebral fractures. *Osteoporos Int*, 1996, 6, s. 284–290.
- 41 **Ringe, J. D. – Coster, A. – Meng, T. – Schacht, E. – Umbach, R.:** Treatment of glucocorticoid-induced osteoporosis with alfacalcidol/calcium versus vitamin D/calcium. *Calcif Tissue Int*, 1999, 63, s. 337–340.
- 42 **Ringe, J. D. – Faber, H.:** Calcium and vitamin D in the prevention and treatment of glucocorticoid-induced osteoporosis. *Clin Exp Rheumatol*, 2000, 18, s. S44–S48.

Ledvinné manifestace u revmatických chorob

MUDr. Hana Ciferská Revmatologický ústav, Praha

MUDr. Jan Vachek Klinika nefrologie VFN, Praha

- 1 **Tesař, V. – Schück, O. et al.:** *Klinická nefrologie*. Praha, Grada Publishing, 2006.
- 2 **Anders, H. J. – Vielhauer, V.:** Renal co-morbidity in patients with rheumatic diseases. *Arthritis Res Ther*, 2011, 29, 13 (3), s. 222.
- 3 **Slobodin, G. – Hussein, A. – Rozenbaum, M. – Rosner, I.:** The emergency room in systemic rheumatic diseases. *Emerg Med J*, 2006, 23 (9), s. 667–671.
- 4 **Merrill, J. T.:** Treatment of systemic lupus erythematosus: a 2012 update. *Bull NYU Hosp Jt Dis*, 2012, 70 (3), s. 172–176.
- 5 **Guo, X. – Nzerue, C.:** How to prevent, recognize, and treat drug-induced nephrotoxicity. *Cleve Clin J Med*, 2002, 69 (4), s. 289–290, 293–294, 296–297.
- 6 **Levey, A. S. – Coresh, J. – Balk, E., et al.:** National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Ann Intern Med*, 2003, 15, 139 (2), s. 137–147.
- 7 **Seymour, A. E. – Spargo, B. H. – Pensa, R. – Am, J.:** Contributions of renal biopsy studies to the understanding of disease. *Pathol*, 1971, 65 (3), s. 550–598.
- 8 **Hochberg, M. C. – Silman, A. J. – Smolen, J. S. – Weinblatt, M. E. – Weisman, M. H.:** Epidemiology and classification of systemic lupus erythematosus. *Rheumatology*, 4. vydání. Philadelphia (PA), Mosby-Elsevier, 2008, s. 1211–1216.
- 9 **Markowitz, G. S. – D'Agati, V. D.:** Classification of lupus nephritis. *Curr Opin Nephrol Hypertens*, 2009, 18 (3), s. 220–225.
- 10 **Bowling, T. K. – Gilkeson, G. S.:** Mechanisms of tissue injury in lupus nephritis. *Arthritis Res Ther*, 2011, 13 (6), s. 250.
- 11 **Houssiau, F.:** Thirty years of cyclophosphamide: assessing the evidence. *Lupus*, 2007, 16 (3), s. 212–216.
- 12 **Houssiau, F. A. – Vasconcelos, C. – D'Cruz, D., et al.:** Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. *Arthritis Rheum*, 2002, 46 (8), s. 2121–2131.
- 13 **Yamaguchi, T. – Ohshima, S. – Tahala, T., et al.:** Renal crisis due to intimal hyperplasia in a patient with mixed connective tissue disease (MCTD) accompanied by pulmonary hypertension. *Intern Med*, 2001, 40 (12), s. 1250–1253.
- 14 **Gaubitz, M.:** Epidemiology of connective tissue disorders. *Rheumatology (Oxford)*, 2006, 45, dopl. 3, s. iii3–4.
- 15 **Dent, T. H. – Johnson, V. W.:** Aspects of mixed connective tissue disease: a review. *J R Soc Med*, 1992, 85 (12), s. 744–746.
- 16 **van der Heijde, D. – van der Helm-van Mil, A. H. – Aletaha, D. – Bingham, C. O., et al.:** EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria. *Ann Rheum Dis*, 2013, 72 (4), s. 479–481.
- 17 **Schiff, M. H. – Whelton, A.:** Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis. *Semin Arthritis Rheum*, 2000, 30 (3), s. 196–208.
- 18 **Irie, F. – Kobayashi, M. – Hirayama, K., et al.:** Rheumatoid arthritis associated with membranous nephropathy and IgA nephritis with necrotizing lesions. *Nephrol Dial Transplant*. 1996, 11 (7), s. 1338–1341.
- 19 **Boers, M. – Croonen, A. M. – Dijkmans, B. A., et al.:** Renal findings in rheumatoid arthritis: clinical aspects of 132 necropsies. *Ann Rheum Dis*, 1987, 46 (9), s. 658–663.
- 20 **Obici, L. – Merlini, G.:** AA amyloidosis: basic knowledge, unmet needs and future treatments. *Swiss Med Wkly*, 2012, 31, s. 142.
- 21 **Kessler, F. – Emery, H. – Dai, L., et al.:** The spectrum of renal tubular acidosis in paediatric Sjögren syndrome. *Rheumatology (Oxford)*, 2006, 45 (1), s. 85–91.
- 22 **Skopouli, F. N.:** Kidney injury in Sjögren's syndrome. *Nephrol Dial Transplant*, 2001, 16, dopl. 6, s. 63–64.
- 23 **Kent, P. D. – Kuchet, C. J. Jr. – Lutra, H. S.:** Relapsing polychondritis. *Curr Opin Rheumatol*, 2004, 16, s. 56–61.
- 25 **Marc, C. – Hochberg, M. D. – Alan, J. – Silman, M. D. – Josef, S. – Smolen, M. D. – Michael, E. – Weinblatt, M. D.:** *Rheumatology*, 2-Volume Set: Expert Consult – Enhanced online features and print (8. 11. 2010), Kindle edition.
- 26 **Basu, N. – Watts, R. – Bajema, I. – Baslund, B. et al.:** EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. *Ann Rheum Dis*, 2010, 69 (10), s. 1744–1750.
- 27 **Hruskova, Z. – Casian, A. – Konopasek, P., et al.:** Long-term outcome of severe alveolar haemorrhage in ANCA-associated vasculitis: a retrospective cohort study. *Scand J Rheumatol*, 2013, 42 (3), s. 211–214.
- 28 **Slot, M. C. – Tervaert, J. W. – Boomsma, M. M.:** Positive classic anti-neutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. *Arthritis Rheum*, 2004, 15, 51 (2), s. 269–273.
- 29 **Vizjak, A. – Rott, T. – Koselj-Kajtna, M. – Rozman, B., et al.:** Histologic and immunohistologic study and clinical presentation of ANCA-associated glomerulonephritis with correlation to ANCA antigen specificity. *Am J Kidney Dis*, 2003, 41 (3), s. 539–549.
- 30 **Agarwal, A. – Bansal, M. – Pandey, R. – Swaminathan, S.:** Bilateral subcapsular and perinephric hemorrhage as the initial presentation of polyarteritis nodosa. *Intern Med*, 2012, 51 (9), s. 1073–1076.
- 31 **Ozen, S.:** The „other“ vasculitis syndromes and kidney involvement. *Pediatr Nephrol*, 2010, 25 (9), s. 1633–1639.
- 32 **Akpolat, T. – Diri, B. – Oğuz, Y., et al.:** Behçet's disease and renal failure. *Nephrol Dial Transplant*, 2003, 18 (5), s. 888–891.
- 33 **Sargur, R. – White, P. – Egner, W.:** Cryoglobulin evaluation: best practice? *Ann Clin Biochem*, 2010, 47 (Pt 1), s. 8–16.
- 34 **Lauletta, G. – Russi, S. – Conteduca, V. – Sansonno, L.:** Hepatitis C virus infection and mixed cryoglobulinemia. *Clin Dev Immunol*, 2012, doi:10.1155/2012/502156.
- 35 **De Vita, S. – Soldano, F. – Idoly, M. – Monti, G., et al.:** Preliminary classification criteria for the cryoglobulinaemic vasculitis. *Ann Rheum Dis*, 2011, 70 (7), s. 1183–1190.
- 36 **Kiremitci, S. – Calayoglu, R. – Ensari, A. – Erbay, B.:** Pathologist's puzzle:

- Membranoproliferative glomerulonephritis-like features in cryoglobulinemic glomerulonephritis. *Pathol Res Pract*, 2012, 15, 208 (4), s. 254–258.
- 37 Davin, J. C. – Clin, J.: Henoch-Schonlein purpura nephritis: pathophysiology, treatment, and future strategy. *Am Soc Nephrol*, 2011, 6 (3), s. 679–689.
- 38 Nakanuta, S. – Hisamatsu, T. – Kikuchi, J., et al.: A case of IgA-related enteropathy complicated with gastrointestinal bleeding and progressive IgA nephropathy: a possible variant Henoch-Schönlein purpura? *Intern Med*, 2010, 49 (16), s. 1755–1756.
- 39 Denon, C. P. – Lapadla, G. – Mouthon, L., et al.: Renal complications and scleroderma renal crisis. *Rheumatology (Oxford)*, 2009, 48, dopl. 3, s. iii32–5.
- 40 Zandman-Goddard, G. – Tweezer-Zaks, N. – Shoenfeld, Y.: New therapeutic strategies for systemic sclerosis—a critical analysis of the literature. *Clin Dev Immunol*, 2005, 12 (3), s. 165–173.
- 41 Lai, K. N. – Li, P. K. – Hawkins, B. – Lai, F. M.: IgA nephropathy associated with ankylosing spondylitis: occurrence in women as well as in men. *Ann Rheum Dis*, 1989, 48 (5), s. 435–437.
- 42 Obici, L. – Raimondi, S. – Lavatelli, F., et al.: Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. *Arthritis Rheum*, 2009, 15, 61 (10), s. 1435–1440.
- 43 Hama, I. – Ilham, R. – Ouzeddoun, N., et al.: Renal amyloidosis due to familial mediterranean fever misdiagnosed. *Indian J Hum Genet*, 2012, 18 (3), s. 363–365.
- 44 Snaith, M. L.: ABC of rheumatology. Gout, hyperuricaemia, and crystal arthritis. *BMJ*, 1995, 25, 310 (6978), s. 521–524.
- 45 Rock, K. L. – Katanka, H. – Lai, J. J.: Uric acid as a danger signal in gout and its comorbidities. *Nat Rev Rheumatol*, 2013, 9 (1), s. 13–23.
- 46 Yu, K. H. – Kuo, C. F. – Luo, S. F. – See, L. C., et al.: Risk of end-stage renal disease associated with gout: a nationwide population study. *Arthritis Res Ther*, 2012, 18, 14 (2), s. R83.
- 47 Weir, M. R.: Renal effects of nonselective NSAIDs and coxibs. *Cleve Clin J Med*, 2002, 69, dopl. 1, s. S153–8.
- 48 Gambaro, G. – Perazella, M. A.: Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors. *J Intern Med*, 2003, 253 (6), s. 643–652.
- 49 Eras, J. – Perazella, M. A.: NSAIDs and the kidney revisited: are selective cyclooxygenase-2 inhibitors safe? *J Med Sci*, 2001, 321 (3), s. 181–190.
- 50 Sander, O. – Herborn, G. – Bock, E. – Rau, R.: Prospective six year follow up of patients withdrawn from a randomised study comparing parenteral gold salt and methotrexate. *Ann Rheum Dis*, 1999, 58 (5), s. 281–287.
- 51 De Bosset, P. – Bitter, T.: Proceedings: Factors governing safety and success of gold salt therapy in rheumatoid arthritis (RA). A prospective study. *Ann Rheum Dis*, 1975, 34 (2), s. 196.
- 52 Avdonin, P. V. – Cottet-Maire, F. – Afanasjeva, G. V. – Loktionova, S. A. – Lhote, P. – Ruegg, U. T.: Cyclosporine A up-regulates angiotensin II receptors and calcium responses in human vascular smooth muscle cells. *Kidney Int*, 1999, 55 (6), s. 2407–2414.
- 53 Akbasli, A. C. – Keven, K. – Erbay, B. – Nebioglu, S.: Changes in oxidative stress in renal graft patients receiving calcineurin inhibitors: cyclosporine versus tacrolimus. *Exp Clin Transplant*, 2012, 10 (5), s. 439–445.
- 54 Abu-Shakra, M. – Shoenfeld, Y.: Azathioprine therapy for patients with systemic lupus erythematosus. *Lupus*, 2001, 10 (3), s. 152–153.
- 55 Houssiau, F.: Thirty years of cyclophosphamide: assessing the evidence. *Lupus*, 2007, 16 (3), s. 212–216.
- 56 Appel, G. B. – Contreras, G. – Dople, M. A., et al.: Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. *J Am Soc Nephrol*, 2009, 20, s. 1103–1112.

Monitorace aktivity revmatoidní artritidy pomocí muskuloskeletálního ultrazvuku

MUDr. Jana Hurňáková Revmatologický ústav Praha

- 1 Šenolt, L.: Klasifikační kritéria revmatoidní artritidy. *Biologická léčba*, 2011, 3, s. 142–146.
- 2 Albers, J. M. – Kuper, H. H. – van Riel, P. L., et al.: Socio-economic consequences of rheumatoid arthritis in the first years of the disease. *Rheumatology*, 1999, 38, s. 423–430.
- 3 Pavelka, K. – Venovský, J.: Doporučení České revmatologické společnosti pro léčbu revmatoidní artritidy. *Čes Revmatol*, 2010, 18, s. 182–191.
- 4 Mann, H.: Využití sonografie při diagnostice a léčbě revmatoidní artritidy. *Čes Revmatol*, 2010, 18, s. 120–124.
- 5 Colebatch, A. N. – Edwards, C. J. – Ostergaard, M., et al.: EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. *Ann Rheum Dis*, 2013, 72, s. 804–814.
- 6 Schmidt, W. A. – Backhaus, M.: What the practising rheumatologist needs to know about the technical fundamentals of ultrasonography. *Best Pract Res Clin Rheumatol*, 2008, 22, s. 981–999.
- 7 Wakefield, R. J. – Brown, A. K. – O'Connor, P. J., et al.: Power Doppler sonography: improving disease activity assessment in inflammatory musculoskeletal disease. *Arthritis Rheum*, 2003, 48, s. 285–288.
- 8 Schmidt, W. A.: Doppler sonography in rheumatology. *Best Pract Res Clin Rheumatol*, 2004, 18, s. 827–846.
- 9 Brown, A. K. – Quinn, M. A. – Karim, Z., et al.: Presence of significant synovitis in rheumatoid arthritis patients with disease modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. *Arthritis Rheum*, 2006, 54, s. 3761–3773.
- 10 Brown, A. K. – Conaghan, P. G. – Karim, Z., et al.: An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. *Arthritis Rheum*, 2008, 58, s. 2958–2967.
- 11 Balsa, A. – de Miguel, E. – Castillo, C.: Superiority of SDAI over DAS-28 in assessment of remission in rheumatoid arthritis patients using power Doppler ultrasonography as a gold standard. *Rheumatology (Oxford)*, 2010, 49, s. 683–690.
- 12 Sciré, C. A. – Montecucco, C. – Codullo, V., et al.: Ultrasonographic evaluation of joint involvement in early rheumatoid arthritis in clinical remission: power Doppler signal predicts short-term relapse. *Rheumatology*, 2009, 48, s. 1092–1097.
- 13 Saleem, B. – Brown, A. K. – Quinn, M., et al.: Can flare be predicted in DMARD treated RA patients in remission, and is it important? A cohort study. *Ann Rheum Dis*, 2012, 71, s. 1316–1321.
- 14 Saleem, B. – Brown, A. K. – Keen, H., et al.: Should imaging be a component of rheumatoid arthritis remission criteria? A comparison between traditional and modified composite remission scores and imaging assessments. *Ann Rheum Dis*, 2011, 70, s. 792–798.
- 15 Taylor, P. C. – Steuer, A. – Gruber, J., et al.: Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis. *Arthritis Rheum*, 2006, 54, s. 47–53.
- 16 Baillet, A. – Gaujoux-Viala, C. – Mouterde, G.: Comparison of the efficacy of sonography, magnetic resonance imaging and

- conventional radiography for the detection of bone erosions in rheumatoid arthritis patients: a systematic review and meta-analysis. *Rheumatology* (Oxford), 2011, 50, s. 1137–1147.
- 17 Szkuclarek, M. – Klarlund, M. – Narvestad, E., et al.: Ultrasonography of metatarsophalangeal joints in rheumatoid arthritis: comparison with magnetic resonance imaging, conventional radiography, and clinical examination. *Arthritis Rheum*, 2006, 2, s. R52.
 - 18 Finzel, S. – Ohrndorf, S. – Englbrecht, M., et al.: A detailed comparative study of high-resolution ultrasound and micro-computed tomography for detection of arthritic bone erosions. *Arthritis Rheum*, 2011, 63, s. 1231–1236.
 - 19 Backhaus, M. – Kamradt, T. – Sandrock, D., et al.: Arthritis of the finger joints: a comprehensive approach comparing conventional radiography, scintigraphy, ultrasound and contrast-enhanced magnetic resonance imaging. *Arthritis Rheum*, 1999, 42, s. 1232–1245.
 - 20 Wakefield, R. J. – Gibbon, W. W. – Conaghan, P. G., et al.: The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: a comparison with conventional radiography. *Arthritis Rheum*, 2000, 43, s. 2762–2770.
 - 21 Døhn, U. M. – Terslev, L. – Szkuclarek, M., et al.: Detection, scoring and volume assessment of bone erosions by ultrasonography in rheumatoid arthritis: comparison with CT. *Ann Rheum Dis*, 2013, 72, s. 530–534.
 - 22 Swen, W. A. A. – Jacobs, J. W. G. – Hubach, P. C. G., et al.: Comparison of sonography and magnetic resonance imaging for the diagnosis of partial tears of finger extensor tendons in rheumatoid arthritis. *Rheumatology* (Oxford), 2000, 39, s. 55–62.
 - 23 Naredo, E. – Collado, P. – Cruz, A., et al.: Longitudinal power Doppler ultrasonographic assessment of joint inflammatory activity in early rheumatoid arthritis: predictive value in disease activity and radiologic progression. *Arthritis Rheum*, 2007, 57, s. 116–124.
 - 24 Funck-Brentano, T. – Gandjbakhch, F. – Etchepare, F., et al.: Prediction of radiographic damage in early arthritis by sonographic erosions and power Doppler signal: a longitudinal observational study. *Arthritis Care Res* (Hoboken), 2013, 65, s. 896–902.
 - 25 Lillegraven, S. – Bøyesen, P. – Hammer, H. B., et al.: Tenosynovitis of the extensor carpi ulnaris tendon predicts erosive progression in early rheumatoid arthritis. *Ann Rheum Dis*, 2011, 70, s. 2049–2050.
 - 26 Naredo, E. – Wakefield, R. J. – Iagnocco, A., et al.: The OMERACT Ultrasound Task Force – Status and Perspectives. *The Journal of Rheumatology*, 2011, 38, s. 2063–2067.
 - 27 Alcalde, M. – D'Agostino, M. A. – Bruyn, G. A., et al.: A systematic literature review of US definitions, scoring systems and validity according to the OMERACT filter for tendon lesion in RA and other inflammatory joint diseases. *Rheumatology* (Oxford), 2012, 51, s. 1246–1260.
 - 28 Scheel, A. K. – Hermann, K. G. – Kahler, E., et al.: A novel ultrasonographic synovitis scoring system suitable for analyzing finger joint inflammation in rheumatoid arthritis. *Arthritis Rheum*, 2005, 52, s. 733–743.
 - 29 Hameed, B. – Pilcher, J. – Heron, C., et al.: The relation between composite ultrasound measures and the DAS28 score, its components and acute phase markers in adult RA. *Rheumatology*, 2008, 47, s. 476–480.
 - 30 Dougados, M. – Jousse-Joulin, S. – Mistretta, F.: Evaluation of several ultrasonography scoring systems for synovitis and comparison to clinical examination: Results from a prospective multi-center study of rheumatoid arthritis. *Ann Rheum Dis*, 2010, 69, s. 828–833.
 - 31 Szkuclarek, M. – Court-Payen, M. – Jacobsen, S., et al.: Interobserver agreement in ultrasonography of the Finger and toe joint inflammation in rheumatoid arthritis. *Arthritis Rheum*, 2003, 48, s. 955–962.
 - 32 Hurňáková, J. – Gatterová, J. – Pavelka, K.: Ultrazvukové skórovací indexy při hodnocení aktivity revmatoidní artritidy. *Čes Revmatol*, 2012, 20, s. 62–72.
 - 33 Naredo, E. – Gamero, F. – Bonilla, G., et al.: Ultrasonographic assessment of inflammatory activity in rheumatoid arthritis: comparison of extended versus reduced joint evaluation. *Clin Exp Rheumatol*, 2005, 23, s. 881–884.
 - 34 Naredo, E. – Rodríguez, M. – Campos, C., et al.: Validity, reproducibility, and responsiveness of a twelve-joint simplified power Doppler ultrasonographic assessment of joint inflammation in rheumatoid arthritis. *Arthritis Rheum*, 2008, 59, s. 515–522.
 - 35 Backhaus, M. – Ohrndorf, S. – Kellner, H., et al.: Evaluation of a novel 7-joint ultrasound score in daily rheumatologic practice: a pilot project. *Arthritis Rheum*, 2009, 61, s. 1194–1201.
 - 36 Ohrndorf, S. – Fischer, I. U. – Kellner, H., et al.: Reliability of the novel 7-joint ultrasound score: results from an inter- and intraobserver study performed by rheumatologists. *Arthritis Care Res* (Hoboken), 2012, 64, s. 1238–1243.
 - 37 Colebatch, A. N. – Edwards, C. J. – Ostergaard, M., et al.: EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. *Ann Rheum Dis*, 2013, 72, s. 804–814.
 - 38 Hammer, H. B. – Terslev, L.: Role of ultrasound in managing rheumatoid arthritis. *Curr Rheumatol Rep*, 2012, 14, s. 438–444.
 - 39 Ozgocmen, S. – Ozdemir, H. – Kiris, A., et al.: Clinical evaluation and Power Doppler sonography in rheumatoid arthritis: evidence for ongoing synovial inflammation in clinical remission. *South Med J*, 2008, 101, s. 240–245.
 - 40 Foltz, V. – Gandjbakhch, F. – Etchepare, F., et al.: Power Doppler ultrasound, but not low-field magnetic resonance imaging, predicts relapse and radiographic disease progression in rheumatoid arthritis patients with low levels of disease activity. *Arthritis Rheum*, 2012, 64, s. 67–76.

Statiny a imunitně zprostředkované myopatie

MUDr. Heřman Mann Revmatologický ústav, Praha

- 1 Pasternak, R. C. – Smith, S. C. Jr. – Bairey-Merz, C. N., et al.: ACC/AHA/NHLBI clinical advisory on the use and safety of statins. *Circulation*, 2002, 106, s. 1024–1028.
- 2 Sathasivam, S.: Statin induced myotoxicity. *Eur J Intern Med*, 2012, 23, s. 317–324.
- 3 Padala, S. – Thompson, P. D.: Statins as a possible cause of inflammatory and necrotizing myopathies. *Atherosclerosis*, 2012, 222, s. 15–21.
- 4 Needham, M. – Fabian, V. – Knezevic, W., et al.: Progressive myopathy with up-regulation of MHC-I associated with statin therapy. *Neuromuscul Disord*, 2007, 17, s. 194–200.
- 5 Grable-Esposito, P. – Katzberg, H. D. – Greenberg, S. A., et al.: Immune-mediated necrotizing myopathy associated with statins. *Muscle Nerve*, 2010, 41, s. 185–190.
- 6 Mohassel, P. – Mammen, A. L.: Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies: A review. *Muscle Nerve*, 2013, doi: 10.1002/mus.23854 (Epub před tiskem).

Moderní terapie ANCA-pozitivních vaskulitid

doc. MUDr. Radim Bečvář, CSc. Revmatologický ústav, Revmatologická klinika 1. LF UK, Praha

- 1 **Jennette, J. C. – Falk, R. J. – Andrassy, K., et al.:** Nomenclature of systemic vasculitides: The proposal of an international consensus conference. *Arthritis Rheum*, 1994, 37, s. 187–192.
- 2 **Hoffman, G. S. – Kerr, G. S. – Leavitt, R. Y., et al.:** Wegener granulomatosis: an analysis of 158 patients. *Ann Intern Med*, 1992, 116, s. 488–498.
- 3 **Bečvář, R.:** Mikroskopická polyangiitida. In: Pavelka, K., et al.: *Revmatologie*. Praha, Galén, 2010, s. 67–68.
- 4 **Bečvář, R.:** Eozinofilní granulomatóza s polyangiitidou. In: Pavelka, K., et al.: *Revmatologie*. Praha, Maxdorf, 2012, s. 408–410.
- 5 **Faurschou, M. – Westman, K. – Rasmussen, N., et European Vasculitis Study Group:** Brief Report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis Rheum*, 2012, 64, s. 3472–3477.
- 6 **Jayne, D.:** Update on the European Vasculitis Study Group trials. *Curr Opin Rheumatol*, 2001, 13, s. 48–55.
- 7 **Pepper, R. J. – Chanouzas, D. – Tarzi, R., et European Vasculitis Study (EUVAS) investigators:** Intravenous cyclophosphamide and plasmapheresis in dialysis-dependent ANCA-associated vasculitis. *Clin J Am Soc Nephrol*, 2013, 8, s. 219–224.
- 8 **Jayne, D.:** Conventional treatment and outcome of Wegener's granulomatosis and microscopic polyangiitis. *Cleveland Clin J Med*, 2002, 69, s. 110–115.
- 9 **Hu, W. – Liu, C. – Xie, H., et al.:** Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. *Nephrol Dial Transplant*, 2008, 23, s. 1307–1312.
- 10 **Stone, J. – Uhlfelder, M. – Hellmann, D., et al.:** Etanercept with conventional treatment in Wegener's granulomatosis: A six month open-label trial to evaluate safety. *Arthritis Rheum*, 2001, 44, s. 1149–1154.
- 11 **Walsh, M. – Chaudhry, A. – Jayne, D.:** Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). *Ann Rheum Dis*, 2008, 67, s. 1322–1327.
- 12 **Jones, R. B. – Tervaert, J. W. – Hauser, T., et European Vasculitis Study Group:** Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. *N Eng J Med*, 2010, 363, s. 211–220.
- 13 **Stone, J. H. – Merkel, P. A. – Spiera, R., et al.:** Rituximab versus cyclophosphamide for ANCA-associated vasculitis. *N Eng J Med*, 2010, 363, s. 221–232.
- 14 **Monach, P. A.:** Maintenance of remission in ANCA-Associate Vasculitis. *Rheumatologist*, 2012, s. 1–2.
- 15 **Smith, R. M. – Jones, R. B. – Jayne D. R.:** Progress in treatment of ANCA-associated vasculitis. *Arthritis Res Ther*, 2012, 14, s. 210–213.